When I was a kid going to Yankee Stadium for a baseball outing the hawkers selling programs would say…. “Ya can’t tell the players without a program!”
Today, that could easily apply to specialty pharmacy. Ya can’t easily tell one biosimilar or cell or gene therapy from another without a program. In years past, several sources (usually PBMs) were kind enough to publish such ‘programs’. But, alas, those days are gone. However, we were pleased to review a nifty ‘program’ (actually more of a hefty booklet) from Ascella Health which recently published its Q2-2023 Specialty & Rare Pipeline Digest….. which we highly recommend.
The Digest includes hefty detail on recent FDA specialty med approvals, pending, and upcoming approvals with PDUFA dates. But wait….. there’s more….!
The Digest charts out cell and gene therapies and biosimilars. It includes detail for each therapy including brand/generic, the manufacturer, route of admin, mechanism, stage in the approval process, and even suggested cost of therapy! And, if that’s not enough, the digest also includes an expert opinion on the impact each therapy may have in its space.
Best yet…. IT IS FREE!
CLICK HERE to access the program…. ummm….. Digest
Visit the Resources section of the AscellaHealth website at https://ascellahealth.com/ and register to receive future communications.
—————————————————————————————-
AscellaHealth Releases Inaugural Specialty & Rare Pipeline Digest
July 27, 2023 — BERWYN, Pa.–(BUSINESS WIRE)–AscellaHealth, a global healthcare and specialty pharmacy solutions organization, today released its Q2 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive resource on new, pending & projected Specialty and Rare Disease drug launches, and cell & gene therapies, biosimilars, and generics. This complimentary, valuable source of industry information supports the specialty drug market needs of stakeholders and decision-makers including pharmaceutical manufacturers, payers and providers, with essential updates on products that are making an impact for millions of individuals living with or affected by rare disease or complex chronic conditions.
